TABLE 2.
Base-case model parameter estimates and data sources.
| Type of parameter | Parameter | Deterministic (USD) | Low | High | Source |
|---|---|---|---|---|---|
| Drug costs (per cycle) | Cycle cost of Gumarontinib | 2,921.90 | 2,377.37 | 3,352.38 | Provided by enterprises |
| Cycle cost of savolitinib | 3,132.03 | 2,548.34 | 3,593.47 | Public database a | |
| Cycle cost of Pemetrexed + cisplatin | 731.82 | 595.43 | 839.63 | Public database a | |
| Disease management costs (once) | Bed charge | 4.15 | 3.38 | 4.76 | Healthcare price list b |
| Nursing | 4.33 | 3.52 | 4.97 | Healthcare price list b | |
| Outpatient expenses | 2.07 | 1.68 | 2.37 | Healthcare price list b | |
| Second-generation gene sequencing | 496.73 | 404.16 | 569.92 | Healthcare price list b | |
| CT | 21.79 | 17.73 | 25.00 | Healthcare price list b | |
| Bone scan | 54.47 | 44.32 | 62.49 | Healthcare price list b | |
| Nuclear craniomagnetism | 52.12 | 42.41 | 59.80 | Healthcare price list b | |
| Fibreoptic bronchoscopy | 25.65 | 20.87 | 29.43 | Healthcare price list b | |
| Bronchoscopy | 89.19 | 72.57 | 102.33 | Healthcare price list b | |
| Serological examination | 1.58 | 1.29 | 1.81 | Healthcare price list b | |
| Routine blood test | 2.72 | 2.22 | 3.12 | Healthcare price list b | |
| Urine routine | 0.49 | 0.40 | 0.56 | Healthcare price list b | |
| Routine fecal matter | 0.48 | 0.39 | 0.55 | Healthcare price list b | |
| Electrocardiography | 9.34 | 7.60 | 10.72 | Healthcare price list b | |
| AE management costs (once) | Peripheral oedema | 0.16 | 0.13 | 0.19 | Zhang et al. (2023) |
| Have a headache | 1.94 | 1.58 | 2.22 | Expert opinion c | |
| Loss of appetite | 1.59 | 1.30 | 1.83 | Expert opinion c | |
| Nauseating | 1.59 | 1.30 | 1.83 | Expert opinion c | |
| Vomiting | 1.59 | 1.30 | 1.83 | Expert opinion c | |
| Elevated alanine aminotransferase | 116.29 | 94.61 | 133.42 | Expert opinion c | |
| Elevated aspartate aminotransferase | 116.29 | 94.61 | 133.42 | Expert opinion c | |
| Have a high-temperature | 1.94 | 1.58 | 2.22 | Expert opinion c | |
| Anemic | 29.99 | 24.40 | 34.41 | Zhang et al. (2023); Ministry of Health, National Development and Reform Commission (2005) | |
| Hypokalaemia | 2.26 | 1.84 | 2.59 | Expert opinion c | |
| Elevated blood creatinine | 21.27 | 17.31 | 24.41 | Expert opinion c | |
| End-of-life care costs (once) | Terminal cost | 7,554.01 | 6,146.25 | 8,666.94 | Zeng et al. (2012) |
| Utility | PFS | 0.804 | 0.589 | 0.883 | Nafees et al. (2017) |
| PD | 0.321 | 0.258 | 0.366 | Nafees et al. (2017) | |
| AE disutility | Oedema | −0.050 | −0.041 | −0.057 | Assumption |
| Have a headache | −0.070 | −0.057 | −0.080 | Doyle et al. (2008) | |
| Loss of appetite | −0.050 | −0.041 | −0.057 | Assumption | |
| Nauseating | −0.125 | −0.101 | −0.143 | Nafees et al. (2017) | |
| Vomiting | −0.125 | −0.101 | −0.143 | Nafees et al. (2017) | |
| Elevated alanine aminotransferase | −0.061 | −0.050 | −0.070 | Sivignon et al. (2020) | |
| Elevated aspartate aminotransferase | −0.061 | −0.050 | −0.070 | Sivignon et al. (2020) | |
| Have a high-temperature | −0.416 | −0.333 | −0.473 | Nafees et al. (2017) | |
| Anemic | −0.119 | −0.097 | −0.136 | Swinburn et al. (2010) | |
| Hypokalaemia | −0.050 | −0.041 | −0.057 | Assumption | |
| Elevated blood creatinine | −0.050 | −0.041 | −0.057 | Assumption | |
| Discount | Cost-utility discount rate | 0.050 | 0.041 | 0.057 | Guideline |
a
Public database: from the China Drug Bidding Database (shuju.menet.com.cn);
b
Healthcare price list: from the list of medical service price items of five provinces (average value);
c
Expert opinion: from medical oncology departments in 17 Chinese tertiary hospitals.